Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| p504 prostate |
|
St. Luke's Medical Center Placental Alkaline Phosphatase * P504 S * Placental Lactogen * Pneumocystis Carinii * Prolactin * Prostate Specific Antigen * Prostatic Acid Phosphatase survivinցp504Œp63ջÙŜʼnňՅ×ŏûûĸÚավŏԄĹExpression ûծp63Șԧավցp504ȘԧավԘկԖʼnňՅÙÚȇզԌԠ,ՌsurvivinȘԧավնŊŏՃŜ p63 and p504S in diagnosis of prostate cancer կԖ×ÐŭԫſChinese BioPortfolio "six transmembrane epithelial antigen of prostate 2 It reacts with the epithelial cells of breast, prostate, kidney, pancreas and . Human P504/alpha Methylacyl CoA Racemase rhuP504s 2 g 5 g- 10 g 310. PATHO-L Correlating prostate biopsies with prostatectomies PATHO-L Correlating prostate biopsies with prostatectomies is a small but definite area of malignancy seen in one, always confirmed with CK34 plus p504. Dr. Michelle S. Hirsch The clinical utility of AMACR (p504) and basal cell cocktail in the evaluation of prostate needle biopsies: A prospective single institution study. EBSCOhost Connection: PROSTATE LEADING NEWLY DIAGNOSED CANCER PROSTATE LEADING NEWLY DIAGNOSED CANCER AMONG MEN; BREAST CANCER LEADS FOR WOMEN. 58 Issue 11, p504-505, 2p. Document Type:, Article P504/alpha Methylacyl CoA Racemase, human, recombinant P504/alpha Methylacyl CoA Racemase, human, recombinant from IMMUNOLOGICAL & BIOCHEMICAL is a recently identified molecular marker for prostate cancer. NSTLŻșçŭżԖԕԍźμԸôûէ Discovery and clinical application of a novel prostate cancer marker: Alpha-methyl acyl Co A racemase ( P504 S). Am J Clin Pathol 2004;122:275-89 bioWORLD - HUMAN P504/ALPHA METHYLACYL COA RACEMASE HUMAN P504/ALPHA METHYLACYL COA RACEMASE. Brand: Model: PRO- 310 also known as P504S, is a recently identified molecular marker for prostate cancer. AMACR - alpha-methylacyl-CoA racemase Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in in comparison with alpha-methylacyl-coenzyme A racemase ( AMACR) (P504-S). Prostate-specific polynucleotide compositions - Patent 7033827 Illustrative compositions comprise one or more prostate-specific This example evaluates the immunoreactivity of P504 is in normal colon and invasive NordiQC mAb clone P504-S (Immunologic, n=1) pAb CP200 & PP200 (BioCare, n=9; As control for AMACR a multitissue block containing both normal prostate, Differential diagnosis of prostate cancer: impact of pattern Prostate cancer offers a wide range of growth patterns depicted in the AMACR (P504 s) is helpful not only in identifying small amount of cancer in IngentaConnect Screening for Prostate Cancer in Military Populations Screening for Prostate Cancer in Military Populations p127; Journal of Urology 168, p922; Journal of Urology 168, p504; Urology (London) 59, p889 Applied Immunohistochemistry & Molecular Morphology - Fulltext Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504 s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;24:6-16. Context Link IngentaConnect Blood Vessels are Regulators of Growth, Diagnostic Diagnostic Markers and Therapeutic Targets in Prostate Cancer p92; Prostate 45, p72; European Urology 30, p191; European Urology 35, p504 ScienceDirect - Annals of Diagnostic Pathology : Human telomerase study was to define the sensitivity and specificity of hTERT in prostate cancer, in comparison with -methylacyl-coenzyme A racemase (AMACR) (P504-S). |
| p504 prostate |
|
photoselective vaporization of prostate postprostatectomy masturbation prostate stimulation prevent prostate problems |